172 related articles for article (PubMed ID: 36601880)
101. Immune checkpoint therapy in colorectal cancer: is first better than last?
Kaneko Y; Naseem Z; Strugnell N; Barnett F; D'Souza B; Sidhu A; Bui A; Pham T
Ann Coloproctol; 2023 Oct; 39(5):439-441. PubMed ID: 37789619
[No Abstract] [Full Text] [Related]
102. Unraveling Emerging Anal Cancer Clinical Biomarkers from Current Immuno-Oncogenomics Advances.
Iseas S; Mariano G; Gros L; Baba-Hamed N; De Parades V; Adam J; Raymond E; Abba MC
Mol Diagn Ther; 2024 Mar; 28(2):201-214. PubMed ID: 38267771
[TBL] [Abstract][Full Text] [Related]
103. Comprehensive genomic profiling reveals prognostic signatures and insights into the molecular landscape of colorectal cancer.
Yang J; Zhao S; Su J; Liu S; Wu Z; Ma W; Tang M; Wu J; Mao E; Han L; Liu M; Zhang J; Cao L; Shao J; Shang Y
Front Oncol; 2023; 13():1285508. PubMed ID: 38023196
[TBL] [Abstract][Full Text] [Related]
104. Immune checkpoint inhibitors in luminal gastrointestinal malignancies: going beyond MSI-H/dMMR, TMB and PD-L1.
Lefler DS; Snook AE; Bashir B
Immunotherapy; 2022 Aug; 14(11):885-902. PubMed ID: 35694998
[TBL] [Abstract][Full Text] [Related]
105. Predictive molecular markers for the treatment with immune checkpoint inhibitors in colorectal cancer.
Du F; Liu Y
J Clin Lab Anal; 2022 Jan; 36(1):e24141. PubMed ID: 34817097
[TBL] [Abstract][Full Text] [Related]
106. Association of KMT2C/D loss-of-function variants with response to immune checkpoint blockades in colorectal cancer.
Liu R; Niu Y; Liu C; Zhang X; Zhang J; Shi M; Zou W; Gu B; Zhu H; Wang D; Yuan H; Li W; Zhao D; Zheng Q; Liu R; Chen W; Ma T; Zhang Y
Cancer Sci; 2023 Apr; 114(4):1229-1239. PubMed ID: 36601880
[TBL] [Abstract][Full Text] [Related]
107. Prediction of Benefit from Checkpoint Inhibitors in Mismatch Repair Deficient Metastatic Colorectal Cancer: Role of Tumor Infiltrating Lymphocytes.
Loupakis F; Depetris I; Biason P; Intini R; Prete AA; Leone F; Lombardi P; Filippi R; Spallanzani A; Cascinu S; Bonetti LR; Maddalena G; Valeri N; Sottoriva A; Zapata L; Salmaso R; Munari G; Rugge M; Dei Tos AP; Golovato J; Sanborn JZ; Nguyen A; Schirripa M; Zagonel V; Lonardi S; Fassan M
Oncologist; 2020 Jun; 25(6):481-487. PubMed ID: 31967692
[TBL] [Abstract][Full Text] [Related]
108. Tumor Mutational Burden Predicting the Efficacy of Immune Checkpoint Inhibitors in Colorectal Cancer: A Systematic Review and Meta-Analysis.
Li Y; Ma Y; Wu Z; Zeng F; Song B; Zhang Y; Li J; Lui S; Wu M
Front Immunol; 2021; 12():751407. PubMed ID: 34659255
[TBL] [Abstract][Full Text] [Related]
109. Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer.
Zaravinos A; Roufas C; Nagara M; de Lucas Moreno B; Oblovatskaya M; Efstathiades C; Dimopoulos C; Ayiomamitis GD
J Exp Clin Cancer Res; 2019 Aug; 38(1):364. PubMed ID: 31429779
[TBL] [Abstract][Full Text] [Related]
110. KMT2C mutation as a predictor of immunotherapeutic efficacy in colorectal cancer.
Ni C; Wang X; Liu S; Zhang J; Luo Z; Xu B
Sci Rep; 2024 Apr; 14(1):8284. PubMed ID: 38594266
[TBL] [Abstract][Full Text] [Related]
111. PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes.
Rosenbaum MW; Bledsoe JR; Morales-Oyarvide V; Huynh TG; Mino-Kenudson M
Mod Pathol; 2016 Sep; 29(9):1104-12. PubMed ID: 27198569
[TBL] [Abstract][Full Text] [Related]
112. Genomic alterations in KMT2 family predict outcome of immune checkpoint therapy in multiple cancers.
Zhang P; Huang Y
J Hematol Oncol; 2021 Mar; 14(1):39. PubMed ID: 33653367
[TBL] [Abstract][Full Text] [Related]
113. KMT2A/C mutations function as a potential predictive biomarker for immunotherapy in solid tumors.
Zhang R; Wu HX; Xu M; Xie X
Biomark Res; 2020 Dec; 8(1):71. PubMed ID: 33298164
[TBL] [Abstract][Full Text] [Related]
114. CRISPR-GEMM Pooled Mutagenic Screening Identifies KMT2D as a Major Modulator of Immune Checkpoint Blockade.
Wang G; Chow RD; Zhu L; Bai Z; Ye L; Zhang F; Renauer PA; Dong MB; Dai X; Zhang X; Du Y; Cheng Y; Niu L; Chu Z; Kim K; Liao C; Clark P; Errami Y; Chen S
Cancer Discov; 2020 Dec; 10(12):1912-1933. PubMed ID: 32887696
[TBL] [Abstract][Full Text] [Related]
115. Association of MUC16 Mutation With Response to Immune Checkpoint Inhibitors in Solid Tumors.
Zhang L; Han X; Shi Y
JAMA Netw Open; 2020 Aug; 3(8):e2013201. PubMed ID: 32845327
[TBL] [Abstract][Full Text] [Related]
116. Role of DNA repair defects in predicting immunotherapy response.
Zhang J; Shih DJH; Lin SY
Biomark Res; 2020; 8():23. PubMed ID: 32612833
[TBL] [Abstract][Full Text] [Related]
117.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
118.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
119.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
120.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
